Clinical Trial Update: Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a four-drug regimen (delamanid, linezolid, pyrazinamide, levofloxacin) for multidrug-resistant tuberculosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis
• Tuberculosis Multidrug-resistant

Drugs mentioned

• Delamanid (delamanid)
• Levofloxacin (Levofloxacin)
• Linezolid (Linezolid)
• Pyrazinamide (pyrazinamide)

Snippet

Sponsor: Boston University | Conditions: Tuberculosis Multi Drug Resistant Active | Phase 3 | Status: WITHDRAWN